Search

everythinglearnresearchcommunity

for

Search:↓

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Certain natural compounds called terpenes may help prevent prostate cancer.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Certain drugs that block specific enzymes can help treat prostate diseases.

Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.

Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.